Idelalisib for treatment of B-cell malignancies-Reference-Cited by-同舟云学术

Idelalisib for treatment of B-cell malignancies

Published:2016-04-15 Issue:8 Volume:73 Page:547-555
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Do Bryan¹,Mace Morgan¹,Rexwinkle Amber¹

Affiliation:

1. The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/73/8/547/28335352/ajhp0547.pdf

Reference44 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Non-Hodgkin lymphoma;Shankland;Lancet,2012

3. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood,2011

4. National Cancer Institute. FDA approval for idelalisib (2014July29). www.cancer.gov/about-cancer/treatment/drugs/fda-idelalisib (accessed 2014 Oct 20).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and synthesis of new 1,2,4-oxadiazole/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors;Frontiers in Chemistry;2024-08-30

2. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome;Pulmonary Pharmacology & Therapeutics;2023-04

3. Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany;Clinical Lymphoma Myeloma and Leukemia;2022-08

4. An efficient synthesis and evaluation of some novel quinazolinone-pyrazole hybrids as potential antiproliferative agents;Synthetic Communications;2021-06-24

5. 4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: A promising scaffold towards bioactive molecules;European Journal of Medicinal Chemistry;2021-03